IL106760A0 - Translocation signal facilitated nuclear delivery of macromolecules - Google Patents

Translocation signal facilitated nuclear delivery of macromolecules

Info

Publication number
IL106760A0
IL106760A0 IL106760A IL10676093A IL106760A0 IL 106760 A0 IL106760 A0 IL 106760A0 IL 106760 A IL106760 A IL 106760A IL 10676093 A IL10676093 A IL 10676093A IL 106760 A0 IL106760 A0 IL 106760A0
Authority
IL
Israel
Prior art keywords
macromolecules
translocation signal
nuclear delivery
facilitated nuclear
signal facilitated
Prior art date
Application number
IL106760A
Other versions
IL106760A (en
Original Assignee
Miles Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Miles Inc filed Critical Miles Inc
Publication of IL106760A0 publication Critical patent/IL106760A0/en
Publication of IL106760A publication Critical patent/IL106760A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Formation Of Insulating Films (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
IL10676093A 1992-08-25 1993-08-22 Protein-nucleic acid hybrid construct for translocating an exogenous nucleic acid into a target cell and nucleus IL106760A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US93507492A 1992-08-25 1992-08-25

Publications (2)

Publication Number Publication Date
IL106760A0 true IL106760A0 (en) 1993-12-08
IL106760A IL106760A (en) 1999-12-31

Family

ID=25466554

Family Applications (1)

Application Number Title Priority Date Filing Date
IL10676093A IL106760A (en) 1992-08-25 1993-08-22 Protein-nucleic acid hybrid construct for translocating an exogenous nucleic acid into a target cell and nucleus

Country Status (10)

Country Link
EP (1) EP0658210A1 (en)
JP (1) JPH08504565A (en)
KR (1) KR950703650A (en)
AU (1) AU674026B2 (en)
CA (1) CA2143308A1 (en)
FI (1) FI950866A (en)
IL (1) IL106760A (en)
NZ (1) NZ255870A (en)
WO (1) WO1994004696A1 (en)
ZA (1) ZA936189B (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5674977A (en) * 1993-02-05 1997-10-07 The Ontario Cancer Institute Branched synthetic peptide conjugate
EP0693939A1 (en) * 1993-04-14 1996-01-31 Roche Diagnostics GmbH Nucleic acid tranfer peptides and their use for injecting nucleic acids into eucaryotic cells
JPH10501681A (en) * 1994-02-22 1998-02-17 ダナ−ファーバー キャンサー インスティチュート Nucleic acid delivery systems and methods for their synthesis and use
US6037329A (en) 1994-03-15 2000-03-14 Selective Genetics, Inc. Compositions containing nucleic acids and ligands for therapeutic treatment
WO1995028494A1 (en) * 1994-04-15 1995-10-26 Targeted Genetics Corporation Gene delivery fusion proteins
US6468981B1 (en) * 1994-07-29 2002-10-22 Emory University Compositions and methods for targeting pharmaceutically active materials to cells containing androgen receptors
JPH09511916A (en) * 1994-11-01 1997-12-02 ベルス，ビンフリート Nucleic acid transfer system
US6051429A (en) * 1995-06-07 2000-04-18 Life Technologies, Inc. Peptide-enhanced cationic lipid transfections
AU727662B2 (en) * 1996-03-26 2000-12-21 Razvan T. Radulescu Peptides having antiproliferative properties
US5962415A (en) * 1996-09-20 1999-10-05 Bristol-Myers Squibb Co. Compositions comprising a peptide inhibitor of nuclear protein translocation and an immunosuppressant and methods of use thereof
US5877282A (en) * 1996-09-20 1999-03-02 Bristol-Myers Squibb Company Peptide inhibitors of nuclear protein translocation having nuclear localization sequences and methods of use thereof
DE19649645A1 (en) * 1996-11-29 1998-06-04 Hoechst Ag Multiple functional ligand system for target cell-specific transfer of nucleotide sequences
WO1998042876A1 (en) * 1997-03-26 1998-10-01 Board Of Regents, The University Of Texas System Methods and compositions for using membrane-penetrating proteins to carry materials across cell membranes
GB9713122D0 (en) * 1997-06-20 1997-08-27 Chiron Spa Novel method of DNA transfer into cells
WO1999007723A1 (en) * 1997-08-07 1999-02-18 University Of Maryland, Baltimore Nucleic acid uptake and release vehicle
PT1129064E (en) 1998-11-12 2008-01-31 Invitrogen Corp Transfection reagents
WO2000045850A2 (en) * 1999-02-06 2000-08-10 Aurx Inc. Drug delivery vehicle
DE19910419A1 (en) * 1999-03-10 2000-09-21 Aventis Pharma Gmbh Target Cell-Specific Multivalent Proteins (MVP)
FR2793414B1 (en) * 1999-05-10 2003-05-23 Centre Nat Rech Scient NUCLEIC ACID-ANTIBODY CONJUGATE FOR DELIVERING FOREIGN NUCLEIC ACID TO CELLS
US6387684B1 (en) * 1999-09-13 2002-05-14 Academia Sinica Topoisomerase 1-mediated DNA delivery
US8128922B2 (en) 1999-10-20 2012-03-06 Johns Hopkins University Superior molecular vaccine linking the translocation domain of a bacterial toxin to an antigen
CN1411512A (en) * 1999-10-20 2003-04-16 约翰霍普金斯大学医学院 Chimeric immunogenic compositions and nucleir acids encoding them
DE10019157A1 (en) * 2000-04-18 2001-11-15 Stefan Duebel Method for introducing ligands into living cells
JP5087201B2 (en) 2000-08-03 2012-12-05 ジョンズ・ホプキンス・ユニバーシティ Molecular vaccine with endoplasmic reticulum chaperone polypeptide linked to antigen
US7198924B2 (en) 2000-12-11 2007-04-03 Invitrogen Corporation Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
WO2002083166A1 (en) * 2001-04-10 2002-10-24 Santen Pharmaceutical Co., Ltd. Interferon-polymer complexes and medicinal use thereof
EP1947116B1 (en) * 2003-02-10 2017-06-21 2-BBB Medicines B.V. Differentially expressed nucleic acids in the blood-brain barrier under inflammatory conditions
US9701725B2 (en) 2003-05-05 2017-07-11 The Johns Hopkins University Anti-cancer DNA vaccine employing plasmids encoding signal sequence, mutant oncoprotein antigen, and heat shock protein
EP1697534B1 (en) 2003-12-01 2010-06-02 Life Technologies Corporation Nucleic acid molecules containing recombination sites and methods of using the same
CA2594040A1 (en) 2005-01-06 2006-07-13 The Johns Hopkins University Rna interference that blocks expression of pro-apoptotic proteins potentiates immunity induced by dna and transfected dendritic cell vaccines
US9085638B2 (en) 2007-03-07 2015-07-21 The Johns Hopkins University DNA vaccine enhancement with MHC class II activators
EP2334693A4 (en) * 2008-07-18 2011-09-21 Chee Keong Choo Methods of long-term culture of eukaryotic cells and uses thereof
WO2016011203A1 (en) 2014-07-15 2016-01-21 Life Technologies Corporation Compositions with lipid aggregates and methods for efficient delivery of molecules to cells

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991009958A2 (en) * 1989-12-21 1991-07-11 Whitehead Institute For Biomedical Research Method of delivering molecules into eukaryotic cells
WO1992005250A1 (en) * 1990-09-25 1992-04-02 University Of Connecticut Prolonging expression of polynucleotides introduced into a cell
DE4139001A1 (en) * 1991-11-27 1993-06-03 Boehringer Mannheim Gmbh PROCESS FOR INJECTION OF NUCLEAR ACIDS IN CELLS
WO1993017102A1 (en) * 1992-02-19 1993-09-02 The Trustees Of The University Of Pennsylvania MODULATIONS OF CELLULAR FUNCTIONS WITH HnRNP PROTEINS
AU671450B2 (en) * 1992-03-20 1996-08-29 Baylor College Of Medicine A DNA transporter system and method of use

Also Published As

Publication number Publication date
FI950866A (en) 1995-04-24
CA2143308A1 (en) 1994-03-03
AU5088593A (en) 1994-03-15
FI950866A0 (en) 1995-02-24
NZ255870A (en) 1996-09-25
WO1994004696A1 (en) 1994-03-03
KR950703650A (en) 1995-09-20
IL106760A (en) 1999-12-31
EP0658210A1 (en) 1995-06-21
AU674026B2 (en) 1996-12-05
JPH08504565A (en) 1996-05-21
ZA936189B (en) 1995-01-10

Similar Documents

Publication Publication Date Title
IL106760A0 (en) Translocation signal facilitated nuclear delivery of macromolecules
IL105218A0 (en) Hexanones and pharmaceutical compositions containing them
HU9303282D0 (en) Pharmaceutical preparations containing hialuronic acid and/or derivatives and/or fragments
IL105223A0 (en) Cyclohexane-ylidenes and pharmaceutical compositions containing them
EP0586256A3 (en) Time measurement system
GB2255503B (en) Improved use of ß2-bronchodilator drugs
GB9226229D0 (en) Detection of macromolecules
GB2264605B (en) Signal compressing system
HU9303283D0 (en) Pharmaceutical preparations containing hialuronic acid and/or derivatives and/or fragments
IL106098A0 (en) Heteroarylnaphthalenes and pharmaceutical compositions containing them
IL97122A0 (en) Aromatase-inhibiting androstendiones and pharmaceutical compositions containing them
IL108073A0 (en) Substituted 6-azaandrostenones their preparation and pharmaceutical compositions containing them
HU9300804D0 (en) Pharmaceutical preparatives
AU587938B2 (en) Combination counting and weighing system
PH25597A (en) DISPENSING OF lIQWUID
HU9303025D0 (en) 4-aryl-3(jheteroaryl-ureido)-quinoline derivatives and pharmaceutical preparatives containing them
IL104417A0 (en) Substituted dihydroindene and-acenaphthene derivatives and pharmaceutical compositions containing them
IL108031A0 (en) Difluoro pentapeptide derivatives and pharmaceutical compositions containing them
CZ87895A3 (en) Pharmaceutical preparation
HUP9602220A2 (en) Substituted 4h-piranes and pharmaceutical preparations containing them
ZA934523B (en) Medicinal preparation
HU9203050D0 (en) Thieno-cyclopentanole-oximes and pharmaceutical preparatives containing them
GB9222591D0 (en) Medicinal remedy
IL106352A0 (en) Pyridoindolo-benzodiazepines and pharmaceutical compositions containing them
GB9216102D0 (en) Pharmaceutical substances

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
RH1 Patent not in force